CL2004000800A1 - Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova - Google Patents

Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova

Info

Publication number: CL2004000800A1
Authority: CL; Chile
Prior art keywords: propellifier; heterocicles; peroxisomes; ppar; underground
Prior art date: 2003-04-15

Application number

CL200400800A

Other languages

English (en)

Spanish (es)

Inventor

Bailey Paul Stuart Humph Simon

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-15

Filing date

2004-04-14

Publication date

2005-03-04

2004-04-14 Application filed by Pfizer filed Critical Pfizer

2005-03-04 Publication of CL2004000800A1 publication Critical patent/CL2004000800A1/es

Links

150000001735 carboxylic acids Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
210000002824 peroxisome Anatomy 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)

CL200400800A 2003-04-15 2004-04-14 Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova CL2004000800A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46321303P	2003-04-15	2003-04-15

Publications (1)

Publication Number	Publication Date
CL2004000800A1 true CL2004000800A1 (es)	2005-03-04

Family

ID=33300053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200400800A CL2004000800A1 (es)	2003-04-15	2004-04-14	Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova

Country Status (25)

Country	Link
EP (1)	EP1615899A1 (pt)
JP (1)	JP2006523671A (pt)
KR (1)	KR20060009846A (pt)
CN (1)	CN1805943A (pt)
AP (1)	AP2005003418A0 (pt)
AR (1)	AR044514A1 (pt)
AU (1)	AU2004230316A1 (pt)
BR (1)	BRPI0409429A (pt)
CA (1)	CA2521915A1 (pt)
CL (1)	CL2004000800A1 (pt)
EA (1)	EA200501462A1 (pt)
EC (1)	ECSP056105A (pt)
IS (1)	IS8033A (pt)
MA (1)	MA27764A1 (pt)
MX (1)	MXPA05010967A (pt)
NL (1)	NL1025946C2 (pt)
NO (1)	NO20055370L (pt)
OA (1)	OA13157A (pt)
PA (1)	PA8600201A1 (pt)
PE (1)	PE20050415A1 (pt)
TN (1)	TNSN05262A1 (pt)
TW (1)	TW200510353A (pt)
UY (1)	UY28266A1 (pt)
WO (1)	WO2004092145A1 (pt)
ZA (1)	ZA200508362B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1997633A (zh) *	2004-05-25	2007-07-11	麦它波莱克斯股份有限公司	作为ppar调节剂的取代的三唑及其制备方法
UA92746C2 (en)	2005-05-09	2010-12-10	Акилайон Фармасьютикалз, Инк.	Thiazole compounds and methods of use
WO2008053131A1 (en)	2006-10-30	2008-05-08	Chroma Therapeutics Ltd.	Hydroxamates as inhibitors of histone deacetylase
RU2480453C2 (ru)	2007-03-08	2013-04-27	Альбирео Аб	Новые соединения
MX2009012613A (es)	2007-05-22	2010-04-21	Achillion Pharmaceuticals Inc	Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
US8106209B2 (en)	2008-06-06	2012-01-31	Achillion Pharmaceuticals, Inc.	Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2010009166A1 (en)	2008-07-14	2010-01-21	Gilead Colorado, Inc.	Oxindolyl inhibitor compounds
US8124764B2 (en)	2008-07-14	2012-02-28	Gilead Sciences, Inc.	Fused heterocyclyc inhibitor compounds
CA2729909A1 (en)	2008-07-14	2010-01-21	Gilead Sciences, Inc.	Imidazolyl pyrimidine inhibitor compounds
CN102123987A (zh)	2008-07-28	2011-07-13	吉里德科学公司	亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
US8283357B2 (en)	2009-06-08	2012-10-09	Gilead Sciences, Inc.	Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko)	2009-06-08	2012-03-30	길리애드 사이언시즈, 인코포레이티드	알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
DE102010055499A1 (de) *	2010-12-22	2011-06-16	W.C. Heraeus Gmbh	Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
US9630929B2 (en)	2011-10-31	2017-04-25	Xenon Pharmaceuticals Inc.	Benzenesulfonamide compounds and their use as therapeutic agents
JP6014155B2 (ja)	2011-10-31	2016-10-25	ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
FR2982858B1 (fr) *	2011-11-18	2013-11-29	Rhodia Operations	Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) *	2011-12-16	2013-12-20	Rhodia Operations	Procede de fabrication de composes comprenant des fonctions nitriles
SG11201408284VA (en)	2012-05-22	2015-02-27	Xenon Pharmaceuticals Inc	N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en)	2012-07-06	2018-09-11	Genentech, Inc.	N-substituted benzamides and methods of use thereof
US9550775B2 (en)	2013-03-14	2017-01-24	Genentech, Inc.	Substituted triazolopyridines and methods of use thereof
MX2015010775A (es)	2013-03-15	2016-04-25	Genentech Inc	Benzoxazoles sustituidos y metodos para usarlos.
CR20160296A (es)	2013-11-27	2016-09-20	Genentech Inc	Benzamidas sustituidas y métodos para usarlas
CN106715418A (zh)	2014-07-07	2017-05-24	基因泰克公司	治疗化合物及其使用方法
JP2018520107A (ja)	2015-05-22	2018-07-26	ジェネンテック，インコーポレイテッド	置換ベンズアミド及びその使用方法
EP3341353A1 (en)	2015-08-27	2018-07-04	Genentech, Inc.	Therapeutic compounds and methods of use thereof
CN108290881B (zh)	2015-09-28	2021-12-07	健泰科生物技术公司	治疗性化合物和其使用方法
US10899732B2 (en)	2015-11-25	2021-01-26	Genentech, Inc.	Substituted benzamides useful as sodium channel blockers
EP3854782A1 (en)	2016-03-30	2021-07-28	Genentech, Inc.	Substituted benzamides and methods of use thereof
AU2017347549A1 (en)	2016-10-17	2019-05-02	Genentech, Inc.	Therapeutic compounds and methods of use thereof
JP2020511511A (ja)	2017-03-24	2020-04-16	ジェネンテック，インコーポレイテッド	ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
AR114263A1 (es)	2018-02-26	2020-08-12	Genentech Inc	Compuestos terapéuticos y métodos para utilizarlos
WO2019191702A1 (en)	2018-03-30	2019-10-03	F. Hoffmann-La Roche Ag	Substituted hydro-pyrido-azines as sodium channel inhibitors
TW202003490A (zh)	2018-05-22	2020-01-16	瑞士商赫孚孟拉羅股份公司	治療性化合物及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE257480T1 (de) *	1999-09-30	2004-01-15	Pfizer Prod Inc	Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren
JP2004520397A (ja) *	2001-02-15	2004-07-08	ファイザー・プロダクツ・インク	増殖性アクチベータ受容体（ｐｐａｒ）化合物

2004
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/xx unknown
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/pt not_active IP Right Cessation
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Ceased
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 EA EA200501462A patent/EA200501462A1/ru unknown
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/ja active Pending
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/ko not_active Ceased
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/zh active Pending
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/es not_active Application Discontinuation
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/es unknown
- 2004-04-13 UY UY28266A patent/UY28266A1/es not_active Application Discontinuation
- 2004-04-14 NL NL1025946A patent/NL1025946C2/nl not_active IP Right Cessation
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/es unknown
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/es unknown
- 2004-04-14 TW TW093110410A patent/TW200510353A/zh unknown
2005
- 2005-09-15 IS IS8033A patent/IS8033A/is unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/es unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/fr unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/fr unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA05010967A (es)	2005-11-28
PE20050415A1 (es)	2005-06-13
MA27764A1 (fr)	2006-02-01
OA13157A (en)	2006-12-13
PA8600201A1 (es)	2005-02-04
WO2004092145A1 (en)	2004-10-28
CN1805943A (zh)	2006-07-19
EP1615899A1 (en)	2006-01-18
WO2004092145A8 (en)	2005-05-12
AP2005003418A0 (en)	2005-12-31
IS8033A (is)	2005-09-15
NL1025946C2 (nl)	2005-02-01
TW200510353A (en)	2005-03-16
AR044514A1 (es)	2005-09-14
UY28266A1 (es)	2004-11-30
JP2006523671A (ja)	2006-10-19
CA2521915A1 (en)	2004-10-28
BRPI0409429A (pt)	2006-04-18
NO20055370L (no)	2006-01-12
KR20060009846A (ko)	2006-02-01
NL1025946A1 (nl)	2004-10-18
EA200501462A1 (ru)	2006-04-28
AU2004230316A1 (en)	2004-10-28
NO20055370D0 (no)	2005-11-14
TNSN05262A1 (fr)	2007-07-10
ZA200508362B (en)	2006-11-29
ECSP056105A (es)	2006-03-01

Publication	Publication Date	Title
CL2004000800A1 (es)	2005-03-04	Compuestos derivados de acidos carboxilicos, sustituidos por heterociclos, composicion farmaceutica, util como modulador del receptor activado proliferador de peroxisomas (ppar-y) para tratar diabetes mellitus no insulina dependiente, sindrome de ova
CL2007002348A1 (es)	2008-08-08	Compuestos heterociclicos, moduladores de la actividad de la estearoil-coa-desaturasa; composicion farmaceutica, util para el tratamiento de enfermedades tales como diabetes, dislipidemias, obesidad, anorexia y acne.
CL2007003854A1 (es)	2008-05-30	Compuestos derivados de ciclopamina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto, util en el tratamiento de desordenes mediados por la via de hedgehog, como cancer.
EA201170305A1 (ru)	2011-10-31	Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
WO2008097428A3 (en)	2008-09-25	Compounds and compositions as modulators of gpr119 activity
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CL2009000889A1 (es)	2010-07-19	Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus.
CL2007001885A1 (es)	2008-01-25	Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis.
CL2011000087A1 (es)	2011-07-01	Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
WO2008001931A3 (en)	2009-09-11	Fused cyclic compounds
CL2012001722A1 (es)	2012-12-14	Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2007002197A1 (es)	2008-02-15	Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
EA200900877A1 (ru)	2010-02-26	Пиперидиновые агонисты gpcr
EA201170304A1 (ru)	2011-10-31	Аналоги глюкозозависимого инсулинотропного полипептида
EA201170302A1 (ru)	2011-10-31	Процессированные аналоги глюкозозависимого инсулинотропного полипетида
CL2008001049A1 (es)	2008-08-08	Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0814252B8 (pt)	2021-05-25	composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
WO2007025613A3 (en)	2007-07-19	Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2007003962A3 (en)	2007-03-08	Gpcr agonists
WO2007003961A3 (en)	2007-03-01	Gpcr agonists
WO2009054423A1 (ja)	2009-04-30	オキサジアゾリジンジオン化合物
ATE555105T1 (de)	2012-05-15	Heterocyclische fxr-bindende verbindungen
MX2012003389A (es)	2012-04-10	Moduladores de gpr40 de pirrolidina.
CL2009001595A1 (es)	2010-07-19	Forma amorfa y cristalina de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol anhidro; composicion farmaceutica que comprende la forma cristalina, util para reducir la glucosa sanguinea, recuperar la sensibilidad a la insulina, tratar la diabetes tipo 2. obesidad.
WO2008040649A3 (en)	2008-05-29	Pyrazine-2-carboxamide derivatives as cb2 receptor modulators